(Q35106468)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12693729%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

review article

1 reference

title

Beta-blockers for heart failure: why, which, when, and where (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12693729%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12693729%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

author name string

John G F Cleland

series ordinal

1

1 reference

6 August 2017

publication date

1 March 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12693729%20AND%20SRC:MED&resulttype=core&format=json

Medical Clinics of North America

2 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12693729%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

volume

87

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12693729%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12693729%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

page(s)

339-371

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12693729%20AND%20SRC:MED&resulttype=core&format=json

The LIDO, HOPE, MOXCON and WASH studies

2 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

The WASH study (Warfarin/Aspirin Study in Heart failure) rationale, design and end-points

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Is aspirin safe for patients with heart failure?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Does aspirin attenuate the effect of angiotensin-converting enzyme inhibitors in hypertension or heart failure?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

The heart failure revascularisation trial (HEART): rationale, design and methodology.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Statistical significance of Veterans Administration Vasodilator Heart Failure Trial results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Sequential neurohumoral measurements in patients with congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Beta-blocking agents in heart failure. Should they be used and how?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Sudden death in heart failure: vascular or electrical?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction. A placebo-controlled, randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Effect of carvedilol on survival in severe chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Autoantibodies against the second extracellular loop of beta1-adrenergic receptors predict ventricular tachycardia and sudden death in patients with idiopathic dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Autoimmunity in idiopathic dilated cardiomyopathy. Characterization of antibodies against the beta 1-adrenoceptor with positive chronotropic effect

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Heart rate dependency of cardiac performance in heart failure patients treated with metoprolol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Effects of beta-blockade with bisoprolol on heart rate variability in advanced heart failure: analysis of scatterplots of R-R intervals at selected heart rates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

The role of subendocardial ischemia in perpetuating myocardial failure in patients with nonischemic congestive cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Haemodynamic, metabolic, and lymphocyte beta 2-adrenoceptor changes following chronic beta-adrenoceptor antagonism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Early use of metoprolol and serum potassium in suspected acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

What is the optimal medical management of ischemic heart failure?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Modification of atherosclerosis by agents that do not lower cholesterol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Carvedilol inhibits vascular smooth muscle cell proliferation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Carvedilol for Heart Failure: Clinical Trials in Progress

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

beta Blockade after myocardial infarction: systematic review and meta regression analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Doxazosin for the treatment of chronic congestive heart failure: Results of a randomized double-blind and placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Vasodilatation with captopril and prazosin in chronic heart failure: double blind study at rest and on exercise

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Cardiovascular effects of dl-nebivolol and its enantiomers--a comparison with those of atenolol.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Carvedilol for prevention of restenosis after directional coronary atherectomy : final results of the European carvedilol atherectomy restenosis (EUROCARE) trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Carvedilol increases plasma vascular endothelial growth factor (VEGF) in patients with chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Changes in plasma endothelin-1 levels reflect clinical response to beta-blockade in chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Effect of beta 1 blockade with atenolol on progression of heart failure in patients pretreated with high-dose enalapril

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

The Euro Heart Failure Survey of The EUROHEART Survey Programme: A survey on the quality of care among patients with heart failure in Europe

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Clinical trials update: IMPROVEMENT-HF, COPERNICUS, MUSTIC, ASPECT-II, APRICOT and HEART.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Diastolic heart failure: neglected or misdiagnosed?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

The cardiac insufficiency talinolol study (CITAS) study design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

The evidence for beta blockers in heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Metoprolol controlled release/extended release in patients with severe heart failure: analysis of the experience in the MERIT-HF study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

The Carvedilol Hibernation Reversible Ischaemia Trial; Marker of Success (CHRISTMAS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Bucindolol Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Predictors of improvement in left ventricular ejection fraction with carvedilol for congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

MIC trial: metoprolol in patients with mild to moderate heart failure: effects on ventricular function and cardiopulmonary exercise testing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Abnormal contractile responses during dobutamine stress echocardiography in patients with idiopathic dilated cardiomyopathy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Beneficial effect of carvedilol on heart rate response to exercise in digitalised patients with heart failure in atrial fibrillation due to idiopathic dilated cardiomyopathy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction: retrospective analysis of the US Carvedilol Heart Failure Trials Program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Effect of concomitant digoxin and carvedilol therapy on mortality and morbidity in patients with chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Clinical events leading to the progression of heart failure: insights from a national database of hospital discharges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Cardiovascular critical event pathways for the progression of heart failure; a report from the ATLAS study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

The effect of enalapril on mortal and morbid events in patients with hypertension and left ventricular dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Clinical trials update: highlights of the scientific sessions of the American Heart Association year 2000: Val HeFT, COPERNICUS, MERIT, CIBIS-II, BEST, AMIOVIRT, V-MAC, BREATHE, HEAT, MIRACL, FLORIDA, VIVA and the first human cardiac skeletal muscle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Combination therapy with carvedilol and amiodarone in patients with severe heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Beta-blocker use and survival in patients with ventricular fibrillation or symptomatic ventricular tachycardia: the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. The Heart-Muscle Disease Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Beta-blockade in heart failure: a comparison of carvedilol with metoprolol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Differential effects of beta-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Nonselective versus selective beta-adrenergic receptor blockade in congestive heart failure: differential effects on sympathetic activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Guidelines for the diagnosis and treatment of chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Effect of propranolol after acute myocardial infarction in patients with congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Are beta-blockers effective in patients who develop heart failure soon after myocardial infarction? A meta-regression analysis of randomised trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Clinical trials update: Highlights of the Scientific Sessions of Heart Failure 2001, a meeting of the Working Group on Heart Failure of the European Society of Cardiology. CONTAK-CD, CHRISTMAS, OPTIME-CHF

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

The CARE-HF study (CArdiac REsynchronisation in Heart Failure study): rationale, design and end-points

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

Unsuspected renal artery stenosis in peripheral vascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

The Carvedilol and ACE-Inhibitor Remodelling Mild Heart Failure EvaluatioN trial (CARMEN)--rationale and design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900173-6

10.1016/S0025-7125(02)00173-6

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12693729%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference